Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Deciphera Pharmaceuticals, LLC
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06287463CT.gov Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neurofibromatosis Type 1
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dcc-3084 (this asset) | Deciphera Pharmaceuticals, LLC | P1 | CC · 43 |
| Trametinib | Novartis Pharmaceuticals | P4 | B |
| Dabrafenib | Novartis Pharmaceuticals | P4 | B |
| Melphalan | Masonic Cancer Center, University of Minnesota | P2 | CCC |
| Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells | Masonic Cancer Center, University of Minnesota | P2 | CCC |
| Busulfanum | Masonic Cancer Center, University of Minnesota | P2 | CCC |
| Cyclophosphamide | Masonic Cancer Center, University of Minnesota | P2 | CCC |
| Fludarabine | Masonic Cancer Center, University of Minnesota | P2 | CCC |
| Rituximab | Masonic Cancer Center, University of Minnesota | P2 | CCC |
+6 more in the Neurofibromatosis Type 1 cohort
Other indications for Dcc-3084
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Castration-Resistant Prostate Carcinoma | — | P1 | CC · 43 |
| Pancreatic Ductal Adenocarcinoma | — | P1 | C · 37 |
| Melanoma | — | P1 | C · 37 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dcc-3084 in Neurofibromatosis Type 1. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dcc-3084-neurofibromatosis-type-1
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →